MX2010010495A - Uso de variantes del factor de crecimiento similar a la insulina (igf-i) pegiladas para el tratamiento de trastornos neuromusculares. - Google Patents

Uso de variantes del factor de crecimiento similar a la insulina (igf-i) pegiladas para el tratamiento de trastornos neuromusculares.

Info

Publication number
MX2010010495A
MX2010010495A MX2010010495A MX2010010495A MX2010010495A MX 2010010495 A MX2010010495 A MX 2010010495A MX 2010010495 A MX2010010495 A MX 2010010495A MX 2010010495 A MX2010010495 A MX 2010010495A MX 2010010495 A MX2010010495 A MX 2010010495A
Authority
MX
Mexico
Prior art keywords
amino acid
treatment
igf
neuromuscular disorders
variants
Prior art date
Application number
MX2010010495A
Other languages
English (en)
Inventor
Friedrich Metzger
Bettina Holtmann
Michael Sendtner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41021043&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010010495(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010010495A publication Critical patent/MX2010010495A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/30Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere el uso farmacéutico de variantes del IGF-I modificado con polietilenglicol (= PEGilado) para el tratamiento, prevención y/o demora de la progresión de trastornos neuromusculares, en particular de la esclerosis lateral amiotrófica (ELA). Más específicamente, la presente invención se refiere al uso de una variante de IGF-I PEGilada para la fabricación de una composición farmacéutica destinada al tratamiento, prevención y/o demora de trastornos neuromusculares, en particular de la ELA, la variante de IGF-I PEGilada se caracteriza porque se deriva de la secuencia de aminoácidos del IGF-I humano de tipo salvaje (SEQ ID NO: 1) y lleva una o dos alteraciones de aminoácido en las posiciones 27, 65 y 68, de modo que uno o dos de los aminoácidos de las posiciones 27, 65 y 68 sea o sean aminoácidos polares, pero no la lisina, y el PEG está unido por lo menos a un residuo lisina.
MX2010010495A 2008-04-03 2009-03-24 Uso de variantes del factor de crecimiento similar a la insulina (igf-i) pegiladas para el tratamiento de trastornos neuromusculares. MX2010010495A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08153994 2008-04-03
PCT/EP2009/053465 WO2009121759A2 (en) 2008-04-03 2009-03-24 Use of pegylated igf-i variants for the treatment of neuromuscular disorders

Publications (1)

Publication Number Publication Date
MX2010010495A true MX2010010495A (es) 2010-10-15

Family

ID=41021043

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010495A MX2010010495A (es) 2008-04-03 2009-03-24 Uso de variantes del factor de crecimiento similar a la insulina (igf-i) pegiladas para el tratamiento de trastornos neuromusculares.

Country Status (19)

Country Link
US (5) US20090253628A1 (es)
EP (1) EP2274016B1 (es)
JP (1) JP5173018B2 (es)
KR (1) KR101273187B1 (es)
CN (1) CN101983074A (es)
AR (1) AR071574A1 (es)
AU (1) AU2009231394B2 (es)
BR (1) BRPI0910338A2 (es)
CA (1) CA2720408C (es)
CL (1) CL2009000803A1 (es)
CR (1) CR11692A (es)
EC (1) ECSP10010516A (es)
ES (1) ES2388827T3 (es)
IL (1) IL208106A (es)
MX (1) MX2010010495A (es)
PE (1) PE20091715A1 (es)
RU (1) RU2010144014A (es)
TW (1) TW200944237A (es)
WO (1) WO2009121759A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
EP2059530B1 (en) 2006-08-31 2012-08-29 F.Hoffmann-La Roche Ag Method for the production of insulin-like growth factor-i
CN101965516A (zh) * 2008-04-03 2011-02-02 弗·哈夫曼-拉罗切有限公司 聚乙二醇化胰岛素样生长因子测定
US20110152188A1 (en) 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
US20140357558A1 (en) * 2011-06-24 2014-12-04 Cold Spring Harbor Laboratory Compositions and methods for treatment of spinal muscular atrophy
US20150265680A1 (en) * 2012-10-24 2015-09-24 Daiichi Sankyo Company, Limited Therapeutic agent for amyotrophic lateral sclerosis
EP3052123A1 (en) 2013-10-02 2016-08-10 Novartis Ag Insulin-like growth factor mimetics for use in therapy
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
AU2018276554A1 (en) 2017-05-30 2019-10-10 Teijin Pharma Limited Anti-IGF-I receptor antibody
JP2020531047A (ja) * 2017-08-16 2020-11-05 エッレジヴ1・ソチエタ・ア・レスポンサビリタ・リミタータ 神経疾患及び神経損傷における使用のためのbpifb4タンパク質のvtftアイソフォーム
WO2020116398A1 (ja) 2018-12-03 2020-06-11 帝人ファーマ株式会社 抗igf-i受容体ヒト化抗体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US5135956A (en) * 1988-10-18 1992-08-04 The Regents Of The University Of California Method of using cytoprotective alcohols to treat neural disease and neural injury
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5158875A (en) * 1989-08-25 1992-10-27 Amgen Inc. Production of biologically active insulin-like growth factor i from high expression host cell systems
NZ236819A (en) * 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
US5861373A (en) * 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
DK0597033T3 (da) * 1991-08-01 1997-06-02 Genentech Inc IGF-1 til forbedring af den neurale tilstand
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
US5395822A (en) * 1993-09-20 1995-03-07 Izumi; Yukitoshi Use of pyruvate to prevent neuronal degeneration associated with ischemia
EP0756494A1 (en) * 1994-05-24 1997-02-05 Amgen Boulder Inc. Modified insulin-like growth factors
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5906976A (en) * 1996-10-22 1999-05-25 Ramot-University Authority For Applied Research And Industrial Development, Ltd. Method and composition for treating neuronal degeneration
AU762351B2 (en) * 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
WO2000040612A1 (en) * 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
US20040014652A1 (en) * 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
EP1674113A1 (en) * 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
AR059088A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una proteina para esclerosis lateral amiotrofica
CL2007002502A1 (es) * 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
EP2059530B1 (en) * 2006-08-31 2012-08-29 F.Hoffmann-La Roche Ag Method for the production of insulin-like growth factor-i

Also Published As

Publication number Publication date
US20150273023A1 (en) 2015-10-01
KR101273187B1 (ko) 2013-06-17
PE20091715A1 (es) 2009-11-17
JP5173018B2 (ja) 2013-03-27
US20110183903A1 (en) 2011-07-28
WO2009121759A2 (en) 2009-10-08
EP2274016B1 (en) 2012-07-25
CA2720408C (en) 2016-09-06
CA2720408A1 (en) 2009-10-08
BRPI0910338A2 (pt) 2020-08-18
US20140073567A1 (en) 2014-03-13
US20090253628A1 (en) 2009-10-08
IL208106A0 (en) 2010-12-30
WO2009121759A3 (en) 2010-03-25
ES2388827T3 (es) 2012-10-19
KR20100119816A (ko) 2010-11-10
CR11692A (es) 2010-12-09
CN101983074A (zh) 2011-03-02
US20170014488A1 (en) 2017-01-19
JP2011518778A (ja) 2011-06-30
ECSP10010516A (es) 2010-11-30
RU2010144014A (ru) 2012-05-27
AU2009231394A1 (en) 2009-10-08
AU2009231394B2 (en) 2013-09-05
AR071574A1 (es) 2010-06-30
TW200944237A (en) 2009-11-01
IL208106A (en) 2015-09-24
EP2274016A2 (en) 2011-01-19
CL2009000803A1 (es) 2010-05-07

Similar Documents

Publication Publication Date Title
MX2010010495A (es) Uso de variantes del factor de crecimiento similar a la insulina (igf-i) pegiladas para el tratamiento de trastornos neuromusculares.
PH12019500644A1 (en) Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
MX2009012675A (es) Tensioactivos reconstituidos que tienen propiedades mejoradas.
MX2014001372A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
NZ621196A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
NZ603811A (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases
NZ630484A (en) Compositions and methods for treatment of metabolic disorders and diseases
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
NZ628126A (en) Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
MY161664A (en) Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
WO2011036443A3 (en) Si protease c- terminal polypeptides and uses thereof for treating inflammation or coagulation disorders
TN2012000393A1 (en) Agonist dr5 binding polypeptides
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
IL199263A (en) Glucagon peptide with enhanced solubility, pharmaceutical composition containing it and its uses for drug preparation
NZ597306A (en) Mesenchymal stem cell differentiation
NZ733366A (en) Purification of iduronate-2-sulfatase
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
MX2012007416A (es) Composiciones y metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis.
MY167804A (en) Treatment of degenerative joint disease
WO2010085700A3 (en) Treatment for obesity
WO2011084685A3 (en) Saposin-a derived peptides and uses thereof
EP4306123A3 (en) Saposin-a derived peptides and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration